CancerData
Not a member yet
37 research outputs found
Sort by
EPTN International Neurological Contouring Atlas
Full text link// 0) {
if(slider_trans.getCurrentSlide() > 0){
event.stopPropagation();
event.preventDefault();
slider_trans.goToPrevSlide();
}
}
if (deltaY..
Data from: Survival prediction of non-small cell lung cancer patients using radiomics analyses of cone-beam CT images
No full textBackground and Purpose: In this study we investigated the interchangeability of planning CT and cone-beam CT (CBCT) extracted radiomic features. Furthermore, this study validates a previously described CT based prognostic radiomic signature for non-small cell lung cancer (NSCLC) patients using CBCT based features.
Material and Methods: One internal dataset of 132 and two external datasets of 62 and 94 stage I-IV NSCLC patients were included in this study. Interchangeability was assessed by performing a linear regression on CT and CBCT extracted features. A two-step correction was applied..
Data from: 4DCT imaging to assess radiomics feature stability: an investigation for thoracic cancers
No full textBackground and Purpose
Quantitative tissue characteristics derived from medical images, also called radiomics, contain valuable prognostic information in several tumour-sites. The large number of features available increases the risk of overfitting. Typically test-retest CT-scans are used to reduce dimensionality and select robust features. However, these scans are not always available. We propose to use different phases of respiratory-correlated 4D CT-scans (4DCT) as alternative.
Materials and Methods
In test-retest CT-scans of 26 non-small cell lung cancer (NSCLC) patients and 4DCT-scans..
Data from: Prognostic value of blood-biomarkers related to hypoxia, inflammation, immune response and tumour load in non-small cell lung cancer – a survival model with external validation
No full textAim: Improve the prognostic prediction of clinical variables for non-small cell lung cancer (NSCLC), by selecting from blood-biomarkers, non-invasively describing hypoxia, inflammation and tumour load.
Methods: Model development and validation included 182 and 181 inoperable stage I-IIIB NSCLC patients treated radically with radiotherapy (55.2%) or chemo-radiotherapy (44.8%). Least absolute shrinkage and selection operator (LASSO), selected from blood-biomarkers related to hypoxia [osteopontin (OPN) and carbonic anhydrase IX (CA-IX)], inflammation [interleukin-6 (IL-6), IL-8, and C-reactive..
Advanced MR Imaging Protocol for Glioblastoma
Full text linkIntroduction:
An MRI protocol has been developed and evaluated on a 3T Siemens scanner in the University of Michigan and led by Dr. Yue Cao. This advanced MRI protocol is intended for identifying the most aggressive components of glioblastoma (GBM) for radiation boosting and for reliable therapy response assessment at multi-institutes.
Background:
It is well known that post-Gd T1 weighted and FLAIR images underestimate and overestimate the tumor volume of GBM, respectively, and cannot assess therapy response reliably. In the last decade, physiological and metabolic imaging..
Data from: Quantitative assessment of Zirconium-89 labeled cetuximab using PETCT imaging in patients with advanced head and neck cancer - a theragnostic approach
No full textBiomarkers predicting treatment response to the monoclonal antibody cetuximab in locally advanced head and neck squamous cell carcinomas (LAHNSCC) are lacking. We hypothesize that tumor accessibility is an important factor in treatment success of the EGFR targeting drug. We quantified uptake of cetuximab labeled with Zirconium-89 (89Zr) using PET/CT imaging.
Seventeen patients with stage III-IV LAHNSCC received a loading dose unlabeled cetuximab, followed by 10 mg 54.5±9.6 MBq 89Zr-cetuximab. PET/CT images were acquired either 3 and 6 or 4 and 7 days post-injection. 89Zr-cetuximab uptake was..
Radiomics Digital Phantom
No full textThe rise of radiomics, the high-throughput mining of quantitative image features from (standard-of-care) medical imaging for knowledge extraction and application within clinical decision support systems to improve diagnostic, prognostic, and predictive accuracy, has significant and substantial implications for the medical community. Radiomic analysis exploits sophisticated image analysis tools and the exponential growth of medical imaging data to develop and validate powerful image-based signatures/models for precision diagnosis and treatment in medicine.
This review describes the process of..
Data from: Benefit of particle therapy in re-irradiation of head and neck patients. Results of a multicenter in silico ROCOCO trial
No full textBackground and Purpose
In this multicentric in silico trial we compared photon, proton, and carbon ion radiotherapy plans for re-irradiation of patients with squamous cell carcinoma of the head and neck (HNSCC) regarding dose to tumour and doses to surrounding organs at risk (OARs).
Material and Methods
Twenty-five HNSCC patients with a second new or recurrent cancer after previous irradiation (70 Gy) were included. Intensity-modulated proton therapy (IMPT) and ion therapy (IMIT) re-irradiation plans to, again, a total dose of 70 Gy were compared to photon therapy delivered with volumetric..
Data from: Nitroglycerin in non-small cell lung cancer: does it impact tumor hypoxia and tumor perfusion? A window-of-opportunity clinical trial.
No full textDespite preclinical evidence that nitric oxide (NO) donors influence both tumor perfusion and hypoxia, in clinical trials nitroglycerin has not been shown to improve the treatment results of all patients with non-small cell lung cancer (NSCLC). Biomarkers are therefore needed to select patients for treatment with NO donors. In this window-of-opportunity study we demonstrate the effect of nitroglycerin on hypoxia in patients using repeated hypoxia PET-imaging: we observed a reduction of hypoxia - quantified by uptake of PET tracer HX4- of varying magnitude upon application of a nitroglycerin..
From Data to Decision - A Knowledge Engineering approach to individualise cancer therapy
Full text linkRadiation oncology is in trouble. In fact, healthcare in general is. The spending on healthcare is rapidly rising, leading to a non-sustainable situation [1]. An aging population can partly explain the increasing costs, but overtreatment plays a large role as well [2]. This particularly happens due to defensive healthcare [3]. On the other hand, overtreatment also occurs due to the longevity of clinical protocols, which can cause inefficiency, as does the technology-push from healthcare industry.
One of the options to reduce the costs is to apply cost-effectiveness analyses or Healthcare...Refer to doi:10.17195/candat.2016.07.0